CD14+ Monocyte Differentiation Into Megakaryocytes for Platelet Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for producing platelets are inefficient, risky, and not clinically applicable due to low efficiency, tumorigenicity, and low polyploidization capacity of megakaryocytes derived from human induced pluripotent stem cells or hematopoietic stem cells, and the limitations of allogeneic blood donations.

Innovation Solution

A method involving the extraction of CD14+ monocytes from blood or bone marrow, their culture and differentiation into megakaryocytes, and subsequent production of platelets, which can be cryopreserved and administered to patients with platelet deficiencies, using a kit containing necessary vessels and reagents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If human induced pluripotent stem cells are used to generate megakaryocytes, then platelet production is enabled, but the process suffers from low efficiency and tumorigenicity risks

Engineering Contradiction:

Improveplatelet production efficiencyVSAvoidtumorigenicity risk

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The invention extracts and utilizes circulating CD14+ monocytes from donor blood as the starting material, rather than using induced pluripotent stem cells. This extraction of the beneficial monocyte population avoids the tumorigenicity risks associated with reprogramming stem cells while maintaining the ability to generate megakaryocytes and platelets through controlled differentiation protocols

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention uses circulating monocytes, which are easily obtainable from donor blood, as a disposable starting material. These monocytes can be differentiated into megakaryocytes and platelets in vitro, providing a safe and efficient source that eliminates the need for risky stem cell reprogramming while allowing for scalable platelet production

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Productivity

If hematopoietic stem cells are used to produce megakaryocytes, then platelet generation is achieved, but the polyploidization capacity is low and the process is not clinically applicable

Engineering Contradiction:

Improvemegakaryocyte generation efficiencyVSAvoidclinical applicability

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The invention changes the starting cell parameter from hematopoietic stem cells to circulating CD14+ monocytes, which have different differentiation characteristics. This parameter change enables more efficient megakaryocyte generation with higher polyploidization capacity, making the process clinically applicable while maintaining controlled differentiation through specific culture conditions

Inventive Principle:

Principle #35Parameter changes

3Quantity of substance

If allogeneic blood donations are used as the exclusive source of platelets, then platelet supply is maintained, but the shelf life is short and pathogen contamination risk exists

Engineering Contradiction:

Improveplatelet supplyVSAvoidplatelet shelf life

Core Design Contradiction:

Quantity of substanceVSDuration of action of stationary object

Solution Approach 1:

The invention performs preliminary differentiation of monocytes into megakaryocytes and platelets in vitro before transfusion. This preliminary action allows for controlled production of platelets with extended shelf life compared to fresh allogeneic donations, while maintaining safety through pathogen-free culture conditions and eliminating the need for immediate transfusion

Inventive Principle:

Principle #10Preliminary action

4Productivity

If bone marrow megakaryocytes are extracted, then platelet production is enabled, but the procedure is invasive requiring bone penetration

Engineering Contradiction:

Improvemegakaryocyte extraction efficiencyVSAvoidprocedure invasiveness

Core Design Contradiction:

ProductivityVSEase of operation

Solution Approach 1:

The invention extracts circulating CD14+ monocytes from donor blood through simple venipuncture, avoiding the invasive bone marrow aspiration procedure. This extraction of monocytes from easily accessible blood provides a non-invasive route to obtain precursor cells for megakaryocyte and platelet production

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention uses circulating monocytes as an intermediary cell type that can be easily obtained from blood and then differentiated into megakaryocytes in vitro. This intermediary approach bypasses the need for direct bone marrow extraction while maintaining the ability to produce functional platelets

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12357659B2Production of megakaryocytes or platelets from monocytes

Publication Date: 2025.07.15 BOARD OF RGT THE UNIV OF TEXAS SYST

AI summary

We disclose a method, comprising extracting cells from a tissue of a donor, wherein the tissue is selected from the group consisting of blood and bone marrow; isolating CD14+ monocytes from the extracted cells; culturing the isolated CD14+ monocytes; differentiating the cultured CD14+ monocytes into megakaryocytes; and administering, to a patient suffering from a platelet deficiency, at least one cell type selected from the group consisting of the differentiated megakaryocytes and platelets produced by the differentiated megakaryocytes. We also disclose a kit comprising at least one material usable in a method; and instructions to perform a method.